- Exchange: Tokyo
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Takeda Pharmaceutical Co Ltd
Add to Portfolio4502:JP
3,300 JPY 75 2.33%As of 02:00:00 ET on 05/25/2012.
News for Takeda Pharmaceutical Co Ltd (4502)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Amylin Said to Draw First-Round Bids From Sanofi, Merck
- Takeda to Buy Multilab to Gain Sales Network in Brazil
- Meda Cash Flow Invites Pipeline Deal at 95% Discount
- Japan Logs Second-Biggest Foreign Asset Haul on Record: Economy
- Lundbeck Sees Lower Libido Risk With New Antidepressant
- Amylin Said to Attract Interest From Pfizer, AstraZeneca
- AstraZeneca Antitrust Fine Should Stand, EU Court Aide Says
- Lundbeck Rises on Results for Experimental Antidepressant
- Takeda Falls Most in 14 Months on Forecast: Tokyo Mover
- Arena Soars After Weight-Loss Pill Wins Panel Backing
- Regeneron’s Arcalyst Fails to Win Panel Backing for Gout
- Dendreon Shares Decline on First-Quarter Net Loss
- Regeneron Drug’s Benefit May Not Outweigh Risk, FDA Says
- Takeda’s Successor Drug to Actos Fails to Win Approval
- Facebook, Krka, Kandi, AstraZeneca: Intellectual Property
- Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil Published May 25, 2012
- Furiex Confirms Takeda’s Announcement on the Acceptance of the European Medicines Agency Submission of Alogliptin for the Published May 23, 2012
- Data from Brentuximab Vedotin (SGN-35) Pivotal Phase II Trial in Patients with Relapsed or Refractory Systemic Anaplastic Large Published May 23, 2012
- Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Published May 23, 2012
- Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes Published May 23, 2012
- Digestive Disease Week Presentations Support Therapeutic Potential for Gattex (teduglutide) as Novel Treatment for Adult Short Published May 21, 2012
- ZYTIGA® (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting Published May 18, 2012
- Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Published May 11, 2012
- Lorcaserin Receives Positive Vote From FDA Advisory Committee Published May 10, 2012
- Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Published May 08, 2012
- Affymax Reports First Quarter 2012 Financial Results Published May 07, 2012
- Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous Published May 07, 2012
- Sunovion Announces Upcoming Availability of ZETONNA™ (ciclesonide) Nasal Aerosol, a Non-Aqueous, Dry Nasal Aerosol Spray for Published May 07, 2012
- NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex® Published May 03, 2012
- BioTrends Announces a New Syndicated Report Series Entitled LaunchTrends®: Omontys Published May 03, 2012
- Amylin Said to Draw First-Round Bids From Sanofi, Merck
- Medicis Sued by Revance Therapeutics Over Wrinkle-Gel Pact
- Three Stocks That Pay While You Wait
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Hungary Stocks: Egis, OTP Bank Move in Budapest Trading
- S&P 500 Analyst Estimate Revisions for May 25
- S&P 500 Analyst Recommendation Changes for May 25
- Astellas, Huawei, Formula One: Intellectual Property
- OTP Bank Rises Second Day, Heads for First Weekly Gain in May
- FDA Gets Senate Approval for $6.4 Billion Review Fee Plan
- Sunovion Settles Patent Dispute With Mylan Over Brovana
- Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
- J&J’s Blood Thinner Rejected by Panel for Expanded Use
- Glaxo Avoids Market for Lemons by Buying Collaborators
- Astellas Pharma Sues Hospira Over Patent for Heart-Test Drug
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page